On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabine fr treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabine or treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabie for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the oehtr hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficac when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On teh otehr hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitaine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabine for treating patients whti advanced pancreatic cancer was not associated whti differences in efficacy when compared whti placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hnd adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo
On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compared with placebo|On the other hand adding infliximab or etanercept to gemcitabine for treating patients with advanced pancreatic cancer was not associated with differences in efficacy when compare with placebo
